IDEXX LABORATORIES INC /DE Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
IDEXX LABORATORIES INC /DE (IDXX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.80% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.80%.
- IDEXX LABORATORIES INC /DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -1.80%.
- IDEXX LABORATORIES INC /DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -1.30%.
- IDEXX LABORATORIES INC /DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -1.50%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.80% 10-K · filed 2026-02-20 | |
| 2024-12-31 | -1.80% 10-K · filed 2026-02-20 | |
| 2023-12-31 | -1.30% 10-K · filed 2026-02-20 | |
| 2022-12-31 | -1.50% 10-K · filed 2025-02-21 | 1.50% 10-K · filed 2023-02-16 |
| 2021-12-31 | -3.60% 10-K · filed 2024-02-22 | 3.60% 10-K · filed 2022-02-16 |
| 2020-12-31 | 5.90% 10-K · filed 2023-02-16 | |
| 2019-12-31 | 3.60% 10-K · filed 2022-02-16 | -3.60% 10-K · filed 2020-02-14 |
| 2018-12-31 | 4.70% 10-K · filed 2021-02-12 | |
| 2017-12-31 | -7.30% 10-K · filed 2020-02-14 | 6.70% 10-K · filed 2018-02-16 |
| 2016-12-31 | 0.00% 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |